Zuie Chin Huang is an entrepreneur and businessperson who founded Legend Biotech Corp., Zai Lab Ltd. and Orion Biotech Opportunities Corp. and who has been at the head of 11 different companies. Presently, Mr. Huang holds the position of Chairman for Windtree Therapeutics, Inc., Executive Chairman at Alaunos Therapeutics, Inc., Chairman of Wuhan Kindstar Co. Ltd., Co-Chairman of Eden Biologics, Inc., Chairman of TriArm Therapeutics (Taiwan) Ltd., Chairman at Tactiva Therapeutics LLC, Chairman for Chime Biologics Ltd., Chief Executive Officer & Director at Orion Biotech Opportunities Corp. and Vice President-Corporate Development of OriGene Technologies, Inc.

He is also General Partner at KPCB China Fund II LP and Managing Partner at Kleiner Perkins Caufield & Byers China and on the board of 10 other companies.

Mr. Huang previously held the position of Principal at Bristol Myers Squibb Co., Venture Partner at Vivo Capital LLC, Partner at Panacea Venture, President for Anesiva, Inc., Project Manager at ALZA Corp., Principal at Tularik, Inc. and Principal at GlaxoSmithKline LLC.

Zuie Chin Huang received an undergraduate degree from the University of California, Berkeley, an MBA from Stanford Graduate School of Business and a graduate degree from Stanford University.